-
<![CDATA[Navigating ARANOTE Trial Findings and Insurance for Prostate Cancer]]>
16 Sep 2025 01:00 GMT
… in treating metastatic hormone-sensitive prostate cancer (mHSPC). Tian Zhang, MD, MHS … ] patients with metastatic hormone sensitive prostate cancer. If they had received hormone … ], enzalutamide [Xtandi], or even abiraterone [Zytiga] because that's the …
-
Prostate Cancer Pipeline Outlook 2025 - Investigational Therapies, Clinical Trials, Drugs And Companies, Medication, By Phase, By ROA, By MOA Delveinsight
29 Aug 2025 21:11 GMT
… out more about prostate cancer drugs @ Prostate Cancer Pipeline Analysis
Prostate Cancer Overview
Prostate cancer is one of … XTANDI (Astellas/Pfizer) and ZYTIGA (Janssen) , alongside newer options such …
-
Decipher test is predictive of chemotherapy benefit in metastatic prostate cancer
27 Aug 2025 17:45 GMT
… which patients with metastatic prostate cancer will benefit from … —was applied to prostate cancer samples obtained from … of patients with metastatic prostate cancer,” said Professor Gerhardt … docetaxel or abiraterone acetate (Zytiga). The median follow- …
-
PARP Inhibitors and Radioligand Therapies Advance Prostate Cancer Care with Biomarker-Driven Strategies
21 Aug 2025 23:55 GMT
… ADT and abiraterone (Zytiga) in metastatic castration-sensitive prostate cancer (mCSPC).
In … in [metastatic castration-sensitive prostate cancer (mCSPC)] in combination with … Pluvicto’s metastatic castration-resistant prostate cancer indication. FDA. March 28 …
-
Pfizer and J&J face new heat as Bayer’s Nubeqa racks up FDA and Korea wins in prostate cancer
21 Aug 2025 01:10 GMT
… to the frontlines of prostate cancer treatment, pitching the … for metastatic castration-sensitive prostate cancer (mCSPC, newly diagnosed … government projections show prostate cancer will become the … the head start: Zytiga, selectively reimbursed since 2021 …
-
Cracking the Code of Prostate Cancer: A Guide to ARPIs
14 Aug 2025 23:23 GMT
… prostate cancer (mHSPC), also known as metastatic castration-sensitive prostate cancer … , is a type of prostate cancer that … Nubeqa) and abiraterone (Zytiga).
Direct head-to- … metastatic hormone-sensitive prostate cancer who had never …
-
Dr Armstrong on Androgen Receptor Inhibitors for Prostate Cancer
11 Aug 2025 21:10 GMT
… prostate cancer.
Enzalutamide (Xtandi), much like its counterparts apalutamide (Erleada), abiraterone (Zytiga … a cornerstone of modern prostate cancer treatment, specifically targeting … the management of metastatic prostate cancer, offering patients improved …
-
Lower dose of abiraterone shows comparable efficacy to standard dose for prostate cancer
29 Jul 2025 22:54 GMT
… of abiraterone acetate (AA; Zytiga; 500 mg) demonstrated … and safer treatment for prostate cancer patients, with minimal … patients with castration-resistant prostate cancer (CRPC). However, the … acetate as effective for prostate cancer treatment. News release. …
-
Metformin Fails to Improve Survival in Metastatic Hormone-Sensitive Prostate Cancer
28 Jul 2025 19:41 GMT
… patients with metastatic hormone-sensitive prostate cancer (mHSPC) did not … (ARPI) such as abiraterone (Zytiga), enzalutamide (Xtandi), or apalutamide … Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: …
-
Carotuximab Combo Proves Safe for Advanced Prostate Cancer
16 Jul 2025 15:56 GMT
… a history of castration-resistant prostate cancer with rising prostate-specific … signaling inhibitor (ARSI), such as Zytiga (abiraterone), Xtandi (enzalutamide), or … the news release. Castration-resistant prostate cancer refers to disease that progresses …
About
© 1995-2025